Anavex says Anavex®2–73 Phase 2B/3 Study Met Primary And Key Secondary Endpoints

Follow us on Google News:
 Anavex says Anavex®2–73 Phase 2B/3 Study Met Primary And Key Secondary Endpoints
Image source: ©2022 Kalkine Media®

Dec 1 (Reuters) - Anavex Life Sciences Corp:


* ANAVEX®2–73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

* KEY SECONDARY ENDPOINT CDR-SB ALSO MET, DEMONSTRATING STATISTICALLY SIGNIFICANT RESULTS

* PLAN TO MEET WITH REGULATORY AUTHORITIES TO DETERMINE NEXT STEPS

* MET PRIMARY ENDPOINTS AND REDUCED CLINICAL DECLINE ON GLOBAL COGNITIVE AND FUNCTIONAL SCALES OVER 48 WEEKS Source text for Eikon: Further company coverage:

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.